Lexicon Pharmaceuticals | LXRX - Assets


Lexicon Pharmaceuticals reported $268.82M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Abbott USD 110.43B 23.72B Mar/2026
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
Agios Pharmaceuticals USD 1.18B 112.24M Mar/2026
Akebia Therapeutics USD 362.52M 14.04M Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
AstraZeneca USD 114.02B 59M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Coherus Biosciences USD 258.34M 258.18M Dec/2025
Eli Lilly USD 116.58B 4.1B Mar/2026
Esperion Therapeutics USD 462.53M 3.36M Mar/2026
Halozyme Therapeutics USD 2.67B 147.4M Mar/2026
Illumina USD 6.56B 85M Mar/2026
Insmed USD 2.08B 188.7M Mar/2026
Ironwood Pharmaceuticals USD 434.57M 37.66M Mar/2026
J&J USD 200.89B 1.68B Mar/2026
Lexicon Pharmaceuticals USD 268.82M 83.83M Mar/2026
MacroGenics USD 217.87M 38.97M Mar/2026
MannKind USD 744.4M 47.78M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Moderna USD 11.49B 850M Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
PTC Therapeutics USD 2.87B 29.66M Mar/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Thermo Fisher Scientific USD 113.28B 2.94B Mar/2026
Ultragenyx Pharmaceutical USD 1.3B 236M Mar/2026
United Therapeutics USD 6.71B 1.17B Mar/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025